Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Hepatitis C: FDA Public Meeting on Peginterferon Plus Ribavirin, Nov. 14

October 18, 2002

On November 14 the Antiviral Drugs Advisory Committee will review the application by Hoffmann-La Roche for approval of peginterferon alfa-2a combined with ribavirin. The meeting will include time for public comment, and comments can also be submitted in writing. If you want to address the committee you need to notify the staff before November 6 and submit a brief written statement about your presentation. Written statements to the Committee should be submitted by November 6.

The meeting will be held November 14, 2002, from 8:30 a.m. to 4 p.m. at the Holiday Inn, Versailles Ballroom, 8120 Wisconsin Avenue, Bethesda, MD. This location is near Washington D.C. and easily reachable by the Red Line subway.

More information is available from the FDA Advisory Committee Information Line, 1-800-741-8138 or 301-443-0572. You will be asked to enter a code; the code for the Antiviral Advisory Committee is 12531.


Comment

Advertisement
We have heard that peginterferon will be approved as a single drug soon, maybe this week. The Advisory Committee will consider the combination with ribavirin. Our understanding is that Roche plans to sell its peginterferon alone as well.

FDA advisory committee meetings are often the best place to learn in-depth information about a new drug before it is approved. They are not called for every new drug application, only for those that present new, difficult, or particularly important issues. Usually a transcript and a summary appear later on the FDA Web site.

The FDA is not required to follow the recommendations of its advisory committees, but it almost always does.


ISSN # 1052-4207

Copyright 2002 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News.
 

Tools
 

Advertisement